Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Exelixis Inc (EXEL) reports robust financial results driven by the cabozantinib franchise, while navigating competitive and ...